文献速递脑血管病癫痫

癫痫患者直接口服抗凝药治疗期间抗癫痫发作药物的安全性

Safety of Antiseizure Medications During Direct Oral Anticoagulant Therapy in Epilepsy.
PubMed 文献 · JAMA Neurol · 2026-01-01

该回顾性队列研究利用TriNetX全球协作网络数据,在9529例接受DOAC的成人癫痫患者中比较不同ASM单药治疗的血栓栓塞、大出血和全因死亡风险。结果显示,与拉莫三嗪/拉考沙胺相比,左乙拉西坦和强酶诱导ASM与更高血栓栓塞风险相关,丙戊酸与更高死亡率和颅内大出血相关。

要点

  • 左乙拉西坦较拉莫三嗪/拉考沙胺血栓栓塞风险更高(HR 1.98),全因死亡风险更高(HR 1.60)。
  • 强酶诱导ASM血栓栓塞风险更高(HR 1.55),但大出血风险更低(HR 0.62)。
  • 丙戊酸全因死亡风险更高(HR 1.49),颅内大出血风险更高(HR 3.01)。

核心结论

  • 在接受DOAC的成人癫痫患者中,ASM选择与不同的血栓栓塞、出血和死亡风险相关,支持ASM选择是可改变的临床结局影响因素。

研究设计与样本

  • 回顾性队列研究,模拟目标试验,针对每种ASM组与活性对照进行1:1倾向评分匹配,数据来自TriNetX全球协作网络(165个国际医疗机构)。
  • 纳入18岁及以上癫痫成人,排除近期使用VKA或强非ASM CYP3A4/P-gp调节剂者及过去一年有大血管事件史者。
  • 最终分析队列为9529例起始治疗者,平均(SD)年龄63(18)岁,女性4869例(51%)。

主要发现

  • 与拉莫三嗪/拉考沙胺匹配比较,左乙拉西坦血栓栓塞风险更高(HR 1.98;95%CI 1.37-2.87),全因死亡风险更高(HR 1.60;95%CI 1.23-2.08),大出血风险相当。
  • 强酶诱导ASM血栓栓塞风险更高(HR 1.55;95%CI 1.02-2.36),大出血风险更低(HR 0.62;95%CI 0.46-0.83)。
  • 丙戊酸全因死亡风险更高(HR 1.49;95%CI 1.09-2.04),颅内大出血风险更高(HR 3.01;95%CI 1.45-6.26)。
  • 在拉莫三嗪/拉考沙胺参照下,约28%的血栓栓塞事件可能可预防。
  • 在VKA治疗成人中,血栓栓塞风险接近无效。

临床怎么用

  • 对于接受DOAC的成人癫痫患者,选择ASM时应考虑血栓栓塞、出血和死亡风险的差异。
  • 与左乙拉西坦、强酶诱导ASM或丙戊酸相比,拉莫三嗪/拉考沙胺可能与更优的安全性相关。

局限性

  • 回顾性观察性设计可能受残余混杂影响。
  • 研究基于电子健康记录数据,可能存在信息偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Concomitant use of antiseizure medications (ASMs) and direct oral anticoagulants (DOACs) is common in epilepsy, but comparative safety data remain limited. OBJECTIVE: To compare risks of thromboembolic events, major bleeding, and all-cause mortality across commonly used ASMs in adults with epilepsy receiving DOACs. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study emulating a target trial for each ASM group against an active comparator; 1:1 propensity score matching in 4 cohorts emulated randomization to estimate the per-protocol outcome of sustained ASM monotherapy. Participant data were acquired from the TriNetX Global Collaborative Network, a federated, deidentified electronic health record platform of 165 health care organizations internationally. Included in the study were adults 18 years or older with epilepsy. Individuals were excluded if there was evidence of recent use of vitamin K antagonists (VKAs) or strong non-ASM cytochrome P450 3A4/P-glycoprotein modulators and if there was a history of major vascular events in the prior year. Participant follow-up began at a prespecified 90-day landmark. Data were analyzed January to March 2026. EXPOSURES: ASM monotherapy with levetiracetam, valproate, moderate enzyme-inducing ASMs, or strong enzyme-inducing ASMs (eg, carbamazepine, phenytoin), each vs lamotrigine or lacosamide (1 pooled reference group of patients taking either drug; hereafter referred to as lamotrigine/lacosamide). MAIN OUTCOMES AND MEASURES: The primary outcomes included primary thromboembolic composite (ischemic stroke, myocardial infarction, pulmonary or systemic/peripheral embolism), major bleeding, and all-cause mortality. Sensitivity analyses included patients treated with VKAs. RESULTS: Of 2.29 million adults (≥18 years) with epilepsy, 40 932 were DOAC eligible, 26 962 had DOAC-ASM overlap within 6 months, 10 209 were monotherapy eligible, and 9529 initiators formed the analytic cohort. Among 9529 initiators (mean [SD] age, 63 [18] years; 4869 female [51%]), there were 5473 (57%) taking levetiracetam, 1395 (15%) taking strong enzyme-inducing ASMs, 1006 (11%) taking valproate, and 382 (4%) taking moderate enzyme-inducing ASMs. In matched analyses vs lamotrigine/lacosamide, levetiracetam was associated with higher thromboembolic risk (hazard ratio [HR], 1.98; 95% CI, 1.37-2.87) and higher all-cause mortality (HR, 1.60; 95% CI, 1.23-2.08), with comparable major bleeding. Strong enzyme-inducing ASMs were associated with higher thromboembolic risk (HR, 1.55; 95% CI, 1.02-2.36) but lower major bleeding (HR, 0.62; 95% CI, 0.46-0.83). Valproate was associated with higher mortality (HR, 1.49; 95% CI, 1.09-2.04) and higher intracranial major bleeding (HR, 3.01; 95% CI, 1.45-6.26). Approximately 28% of thromboembolic events were potentially preventable under a lamotrigine/lacosamide reference. In VKA-treated adults, thromboembolic risks were near null. CONCLUSIONS AND RELEVANCE: Results suggest that in adults with epilepsy who are treated with DOACs, ASM selection was associated with distinct thromboembolic, bleeding, and mortality risks, supporting ASM choice as a modifiable contributor to clinical outcomes.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Schubert KM, Ferreira-Atuesta C, Soma A, et al. Safety of Antiseizure Medications During Direct Oral Anticoagulant Therapy in Epilepsy. JAMA Neurol. 2026. PMID: 42606848. doi:10.1001/jamaneurol.2026.2712

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。